Cancer Therapeutic Procedure
Ikena Oncology Cuts Hippo Pathway Inhibitor, Lays Off Half of Staff in Strategic Reprioritization
Ikena Oncology, Hippo pathway inhibitor, TEAD1-selective, layoffs, strategic update, biotech industry, clinical trials, cancer treatment
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment
Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO
J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks
J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.
Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates
Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.
AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody
AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing
AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.
AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility
AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.
FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer
FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.